Pyridam Farma Tbk PT
IDX:PYFA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
89
1 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pyridam Farma Tbk PT
Pyridam Farma Tbk PT
Cash & Cash Equivalents
Pyridam Farma Tbk PT
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Cash & Cash Equivalents
Rp505.4B
|
CAGR 3-Years
129%
|
CAGR 5-Years
216%
|
CAGR 10-Years
70%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Cash & Cash Equivalents
Rp64.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Cash & Cash Equivalents
Rp3.7T
|
CAGR 3-Years
-7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Cash & Cash Equivalents
Rp437.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
42%
|
CAGR 10-Years
26%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Cash & Cash Equivalents
Rp470.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Cash & Cash Equivalents
Rp505.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
Pyridam Farma Tbk PT
Glance View
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.
See Also
What is Pyridam Farma Tbk PT's Cash & Cash Equivalents?
Cash & Cash Equivalents
505.4B
IDR
Based on the financial report for Sep 30, 2024, Pyridam Farma Tbk PT's Cash & Cash Equivalents amounts to 505.4B IDR.
What is Pyridam Farma Tbk PT's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
70%
The average annual Cash & Cash Equivalents growth rates for Pyridam Farma Tbk PT have been 129% over the past three years , 216% over the past five years , and 70% over the past ten years .
You don't have any saved screeners yet
